WASHINGTON -- Patients with IgG4-related disease appeared to benefit from inebilizumab (Uplizna), currently approved for ...

Acepodia (6976:TT), a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) and allogeneic gamma delta 2 (γδ2) T cell platforms, ...

An international, phase 3 clinical trial led by investigators at Mass General Brigham could improve the treatment of a rare disease that can cause debilitating symptoms.

Ocular autoimmune disease involves the immune system attacking the tissues of the eye. These diseases typically manifest through an autoantibody response targeting the retina, uvea, vitreous, and ...

which is in a phase 3 trial as a treatment for IgG4-related disease (IgG4-RD), phase 2/3 in warm autoimmune haemolytic anaemia (wAIHA), and phase 2 in multiple sclerosis (MS) and systemic lupus ...

Amgen (NASDAQ:AMGN) added that a Phase 3 trial called MITIGATE for Uplizna in the treatment of IgG4-related disease met its ...

Zenas BioPharma's obexelimab demonstrates strong clinical results, but financial uncertainties remain. See more on ZBIO stock and the current market outlook.

My name is Julianne, and I will be your conference facilitator today for Amgen's third-quarter 2024 financial results conference call. (Operator Instructions) I would now like to introduce Justin ...

IND clearance paves the way for Acepodia to enter the clinic for the first time with its autoimmune program ACE1831 is an allogeneic gamma delta T cell therapy ...